- Home
- SAVA vs PLX Comparison
SAVA vs PLX Comparison
Compare SAVA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- PLX
- Stock Information
- Founded
- SAVA 1998
- PLX 1993
- Country
- SAVA United States
- PLX Israel
- Employees
- SAVA N/A
- PLX N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAVA Health Care
- PLX Health Care
- Exchange
- SAVA Nasdaq
- PLX Nasdaq
- Market Cap
- SAVA 135.9M
- PLX 160.2M
- IPO Year
- SAVA N/A
- PLX 1998
- Fundamental
- Price
- SAVA $2.75
- PLX $2.22
- Analyst Decision
- SAVA Buy
- PLX
- Analyst Count
- SAVA 3
- PLX 0
- Target Price
- SAVA $111.50
- PLX N/A
- AVG Volume (30 Days)
- SAVA 3.4M
- PLX 553.9K
- Earning Date
- SAVA 02-26-2025
- PLX 03-13-2025
- Dividend Yield
- SAVA N/A
- PLX N/A
- EPS Growth
- SAVA N/A
- PLX N/A
- EPS
- SAVA N/A
- PLX N/A
- Revenue
- SAVA N/A
- PLX $45,667,000.00
- Revenue This Year
- SAVA N/A
- PLX N/A
- Revenue Next Year
- SAVA N/A
- PLX $90.00
- P/E Ratio
- SAVA N/A
- PLX N/A
- Revenue Growth
- SAVA N/A
- PLX N/A
- 52 Week Low
- SAVA $2.23
- PLX $0.82
- 52 Week High
- SAVA $42.20
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- PLX 74.10
- Support Level
- SAVA $2.65
- PLX $2.11
- Resistance Level
- SAVA $2.83
- PLX $2.36
- Average True Range (ATR)
- SAVA 0.24
- PLX 0.12
- MACD
- SAVA 0.59
- PLX 0.00
- Stochastic Oscillator
- SAVA 52.75
- PLX 77.42
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.